Jensen Huang: $3 trillion in revenue is possible for NVIDIA in the near-future | Lex Fridman
Jensen Huang discusses NVIDIA's potential to reach $3 trillion in revenue, arguing that AI intelligence is a scalable, valuable product that will dramatically increase global GDP and computational spending. He believes physical and supply chain limitations won't prevent this growth, as NVIDIA is creating entirely new markets rather than competing for existing market share.
Summary
In this transcript, Jensen Huang presents a comprehensive vision for NVIDIA's massive growth potential, centered around the transformative nature of artificial intelligence as a scalable product. He explains that AI intelligence tokens will command premium pricing, with some specialized tokens potentially costing $1,000 per million tokens in the near future. Huang frames NVIDIA's data centers not as storage facilities but as 'product generation units' that create valuable, revenue-generating intelligence. He predicts this transformation will accelerate global GDP growth and increase computational spending by 100 times compared to historical levels, driven by new drug discoveries, products, and services enabled by AI. Regarding NVIDIA's path to $3 trillion in revenue, Huang argues there are no physical limitations preventing this growth, noting that their supply chain burden is distributed across 200 partner companies, making massive scaling feasible. He dismisses past predictions that capped NVIDIA's growth potential, explaining these weren't based on first-principle reasoning. A key distinction Huang makes is that NVIDIA isn't in the market share business - they're creating entirely new markets rather than taking share from existing competitors, which makes their growth potential harder for people to imagine but ultimately more substantial. He expresses confidence that each GPU Technology Conference (GTC) will make this vision increasingly real and tangible to observers.
Key Insights
- Jensen Huang argues that specialized AI intelligence tokens will command premium pricing of $1,000 per million tokens in the near future
- Huang predicts that the percentage of global GDP spent on computation will be 100 times higher than in the past because computers are becoming product generation units rather than storage units
- Jensen Huang states that $3 trillion in revenue is possible for NVIDIA because there are no physical limits preventing this growth and their supply chain burden is shared across 200 companies
- Huang dismisses past CEO predictions that capped NVIDIA's growth potential, arguing these weren't based on first-principle reasoning
- Jensen Huang explains that NVIDIA isn't competing for market share but creating entirely new markets, making their growth potential harder to imagine but more substantial
Topics
Transcript
[0:03] intelligence, as it turns out, you know, is a scalable product. There's extremely high intelligence products, tokens that you could that are used for specialized things. People be willing to pay, you know, the idea that somebody's willing to pay $1,000 per million tokens is just around the corner. It's not if, it's only when. And so so now we're seeing that the commodity that this factory makes is actually valuable and is revenue generating and profit [0:33] generating. How now the question is how many of these factories can does the world need? How much how many tokens does the world need? And um how much is society willing to pay for these tokens? And what would happen…
Full transcript available for MurmurCast members
Sign Up to AccessMore from Lex Clips
Do antipsychotic drugs work? | Andrew Scull and Lex Fridman
Andrew Scull discusses the efficacy and serious side effects of antipsychotic drugs, explaining that while they help some patients, many are non-responders, and the medications carry substantial risks including tardive dyskinesia, weight gain, metabolic syndrome, and cognitive dulling. The landmark CATIE study revealed that newer, expensive second-generation antipsychotics are no more effective than older first-generation drugs, with 67-82% of patients dropping out due to inefficacy or intolerable side effects.
Surprising origin of antipsychotic drugs | Andrew Scull and Lex Fridman
Andrew Scull explains how chlorpromazine, an antihistamine synthesized in the 1880s, was accidentally discovered to have psychiatric applications in the 1950s through French Navy lieutenant Alain Laborit's experiments. The drug's rapid adoption was driven by pharmaceutical companies' aggressive marketing to politicians and hospital administrators rather than by psychiatrists' initial enthusiasm, transforming it from a 'major tranquilizer' into the first 'antipsychotic' drug.
Cognitive Behavioral Therapy (CBT) vs Psychoanalysis | Andrew Scull and Lex Fridman
Andrew Scull discusses how clinical psychology and cognitive behavioral therapy (CBT) emerged after WWII as alternatives to psychoanalysis, becoming dominant through better empirical evidence, shorter treatment duration, and federal funding advantages. CBT's symptom-focused approach proved more measurable and reproducible than psychoanalytic theory, though its effectiveness remains limited for serious mental disorders.
Do anti-depressant drugs work? | Andrew Scull and Lex Fridman
Andrew Scull discusses the history and efficacy of antidepressants, particularly SSRIs like Prozac, explaining that while they statistically outperform placebo, the clinical improvement is often marginal and comes with significant side effects including sexual dysfunction and withdrawal difficulties. He also addresses 'diagnostic creep' in psychiatry, where conditions become increasingly broadly defined and diagnosed over time.
How drugs and psycho-pharmacology changed mental health | Andrew Scull and Lex Fridman
Andrew Scull traces the accidental discovery of psychopharmacology, beginning with chlorpromazine's unexpected psychiatric effects in the 1950s, and discusses how pharmaceutical companies transformed mental health treatment while also introducing serious side effects like tardive dyskinesia and metabolic complications that remain inadequately addressed.